Business Context and Reporting Period
This Form 8-K, filed on August 9, 2018, reports on events occurring on August 8, 2018, involving OvaScience, Inc. (the "Registrant"). The filing details the entry into a definitive merger agreement with Millendo Therapeutics, Inc. ("Millendo"). Under the agreement, a wholly-owned subsidiary of OvaScience will merge with Millendo, with Millendo surviving as a wholly-owned subsidiary of OvaScience. The transaction is structured as a reverse merger where Millendo shareholders will own approximately 80% of the combined company, and OvaScience shareholders will own approximately 20%. Upon closing, OvaScience will change its name to Millendo Therapeutics, Inc.
Key Financial Metrics and Transaction Terms
The filing does not provide standard financial performance metrics such as revenue, profit, or cash flow for the reporting period, as this is a current report regarding a corporate transaction rather than a periodic financial report. However, the following financial terms and conditions are disclosed:
- Ownership Structure: Pro forma ownership is approximately 80% for Millendo investors and 20% for OvaScience shareholders, subject to adjustments based on net cash and additional financing.
- Exchange Ratio Adjustment: The ratio will be adjusted if OvaScience's net cash at closing is less than $40.0 million or greater than $42.0 million.
- Additional Financing: Certain existing Millendo stockholders have agreed to purchase $30 million of Millendo common stock prior to the merger closing, subject to conditions.
- Termination Fees:
- Standard termination fee: $3,000,000 payable by either party under specified circumstances.
- Expense reimbursement: Up to $1,000,000.
- Break-up fee: Millendo may be required to pay OvaScience $15,000,000 in certain specified circumstances.
- Stock Split: OvaScience will effect a reverse stock split to satisfy Nasdaq listing requirements.
Material Changes and Corporate Actions
The primary material change is the proposed merger with Millendo Therapeutics, Inc., which represents a fundamental shift in the company's business focus and capital structure. Additional material actions include:
- Board Composition: The post-merger Board of Directors is expected to have seven members: six designated by Millendo and one by OvaScience.
- Voting Agreements: Stockholders holding approximately 73% of Millendo capital stock and 5% of OvaScience common stock have entered into voting agreements to support the merger.
- Lock-Up Agreements: Key executives and stockholders of both companies have agreed to restrictions on share transfers for 180 days following the closing.
- Bylaw Amendment: OvaScience amended its bylaws to require that certain stockholder actions be brought exclusively in the Court of Chancery of the State of Delaware.
- Executive Compensation: An amendment to the retention agreement for Jonathan Gillis, Senior Vice President - Finance, was approved to clarify severance terms in the event of a Qualified Termination.
Guidance, Outlook, Risks, and Contingencies
Outlook and Conditions: The merger is subject to several closing conditions, including stockholder approval from both companies, continued listing on the Nasdaq Stock Market, and satisfaction of minimum net cash thresholds. The transaction is intended to qualify as a tax-free reorganization under Section 368(a) of the Internal Revenue Code.
Risks and Contingencies: The filing highlights significant risks, including the failure to obtain stockholder approval, uncertainties regarding the timing of consummation, risks to Nasdaq listing status, and the ability to accurately estimate transaction-related expenses. Management notes that actual results could differ materially from expectations due to regulatory, competitive, and economic factors.
Unusual Items: The filing includes a standard disclaimer that the Merger Agreement contains representations and warranties made solely for the benefit of the parties and should not be relied upon as characterizations of the actual state of facts.
Important Facts for Investor Verification
- Verify the final Exchange Ratio and ownership percentages once the net cash balance at closing is determined.
- Confirm the outcome of the stockholder votes required for both OvaScience and Millendo.
- Monitor the status of the $30 million additional financing commitment by Millendo stockholders.
- Review the upcoming proxy statement and prospectus for detailed financial information and risk factors.
- Check for any updates regarding the reverse stock split ratio and the name change to Millendo Therapeutics, Inc.